Tropicamide is a mydriatic drug used as eye-drops for diagnostic or therapeutic purposes. From 2013, a diverted use by intravenous route has been suspected in Eastern Europe in opioids users. To date, no signal of misuse has been identified in France. The aims of this study were to investigate any early signals of a diverted use of tropicamide eye drops and to collect information regarding motives for the misuse and tropicamide-induced effects.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Tropicamide may cause euphoria, confusional state, delusions or visual hallucinations at high doses.
• The potential exists for misuse and abuse of atropinic drugs, in patients with psychiatric comorbidities notably.
• An early signal of intravenous administration of tropicamide has been identified in Europe (but not in France) in opioids users.
WHAT THIS STUDY ADDS
• A first signal of a diverted use of tropicamide eye drops was identified in several areas in France.
• Euphoria and hallucinations are sought by users as well as a decrease in opioid consumption.
• The easy access and the low cost of tropicamide eye drops are factors contributing to their potential misuse.
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The misuse of atropinic drugs has been documented in particular in severe mental illness subjects and seems to occur frequently with trihexyphenidyl 'to get high' [3, 4] . Other drugs such as diphenhydramine and dimenhydrinate, which also have antihistaminic properties, are available without a prescription and used by teenagers, young adults and patients with psychotic disorders for recreational purposes [5, 6] . Indeed, users seek effects like hallucinations, euphoria (i.e., general well-being or relaxation), an alleviation of anxiety or depressive symptoms or a stimulating effect that receptor-M1 blocking agents can induce [3, 7] . Among atropinic drugs, tropicamide is an ophthalmic solution indicated for therapeutic or diagnostic procedures, used for a very short-term exposure period at starting doses of one drop (150 μg of tropicamide) and not exceeding 3 ml of the solution. When it reaches blood circulation, atropine-like effects including confusional state, delirium, acute psychosis, visual hallucinations, hyperexcitability or drowsiness may appear especially at high dosages, in children or elderly people [8, 9] . From 2013 in Italy, a diverted use of tropicamide has been suspected by some pharmacists, who have observed an abnormal increase in eye drop sales [10] . In its annual report for 2014, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has identified intravenous tropicamide administration as a new practice in opioid abusers [11] . Recently, in France, the first report of several falsified prescriptions involving tropicamide eye drops has been notified by some community pharmacists in the Midi-Pyrénées area (Southwest France).
The present paper aimed to investigate an early signal of a diverted use of tropicamide eye drops. We also intended to provide clues to determine reasons for misusing this drug and describe tropicamide-induced effects.
Methods
We designed a multisource investigation reviewing data reported to the French Addictovigilance Network as well as published data and informal information.
Regional data
Data derived from sentinel community pharmacies. In connection with the Regional Health Authority, the Toulouse Addictovigilance Centre centralizes observations derived from the regional network of community pharmacists related to abuse, dependence or misuse of drugs. These sentinel community pharmacies are distributed across the Midi-Pyrénées and Limousin areas (Southwest France). Data were collected up to 5 July 2016.
Data related to tropicamide reimbursement. Data concerning tropicamide dispensing in the Midi-Pyrénées and Limousin areas were obtained from the local healthcare insurance office for 2014 as well as the 10 ml vial containing tropicamide (not the single-dose containers). The information included the number of reimbursed tropicamide boxes for a given patient (with an anonymous identifier). Elderly patients over 65 years old were excluded from the analysis.
National data
Data related to suspicious requests from the OSIAP survey. OSIAP (Ordonnances Suspectes, Indicateur d'Abus Possible) is a French survey performed by the French Addictovigilance Network among community pharmacists. This study aims to collect forged and falsified prescriptions to identify drugs liable to be diverted from their medical use or at risk of abuse or dependence [12, 13] . Prescriptions recorded from 2001 to 2015 were analysed. Beta-blocker eye drops (except those in combination) were used as comparators (Table 1) and 95% confidence intervals (CI) were estimated using a Poisson approximation for rare events.
Data related to tropicamide reimbursement. Open Medic is a public platform providing aggregate data on reimbursed drugs delivered in French community pharmacies [14] . We collected information for the 10 ml tropicamide package in the 20-59 age group. Data were extracted for 2014 and 2015.
International data Data related to pharmacovigilance reporting within VigiBase ® .
In the World Health Organisation database, called VigiBase ® ,
the MedDRA terms described in Table 2 were selected for tropicamide and the six beta-blocker comparators ( Media and Internet forums. Random online searches were performed to evaluate the information disclosed to the general public and between drug users. The following specific websites were visited on 4 and 5 July 2016: bluelight.org, psychoactif.org, psychonaut.com, erowid.org, drugs-forum.com, asud.org, drogues-info-service.fr, drogues. blog.lemonde.fr, using keywords in French or in English: 'tropicamide', 'mydriaticum', 'visumidriatic', 'mydriatics', 'eye drops', 'legal high', 'new substances' and followed related discussions.
Results
Regional and national data Suspicious requests and falsified prescriptions. The first suspicious requests were notified to the Toulouse Addictovigilance Centre on September 2014 by community pharmacists located in and around Toulouse. Since then and until 5 July 2016, 65 pharmacies (including several on-duty pharmacies) have reported 91 suspicious attempts to obtain tropicamide eye drops (Figure 1 ). Initially located in Toulouse city and close surroundings, requests spread throughout other Midi-Pyrénées departments (Figure 2 ). Among the 91 reports, 59 (64.8%) involved a prescription form including photocopies of six different prescriptions identified in 46 (78%) cases. One of these prescriptions was written in Russian and presented in four pharmacies. Concerning spontaneous requests, a repetitive pattern was identified by pharmacists: individuals, men exclusively, in their 40s, native Eastern Europe, ask for tropicamide eye drops to send to a family member back home, due to a stock shortage in their countries, etc. Some pharmacists have reported insistent even aggressive behaviours when faced with professional refusal to comply. According to data from the national OSIAP survey, in 2006, one suspicious prescription involved tropicamide along with tobramycin/ dexamethasone eye drops and buprenorphine. No other suspicious prescription mentioning tropicamide was (Figure 3) . One subject purchased a kit containing syringes (sterile kit available in pharmacies for intravenous drug users) while presenting a prescription of tropicamide eye drops. (Table 2) , we have identified two cases of abuse/dependence with tropicamide, reported in two men (age unknown) in 2016 in Germany and Egypt with a diverted intravenous route in one case. Regarding the comparators, five cases of abuse/dependence were identified (three with timolol in 1996, one with betaxolol in 2000 and one with carteolol in 1997). For these five cases, the drug was administrated by intraocular route.
Unofficial data. The diverted use of tropicamide eye drops has been covered on the Internet by some journalists and specific websites since 2011. However, since this date, newspaper articles are quite rare, as are discussions among drug users. On the other hand, the topic seems of interest as highlighted by the number of occurrences of tropicamiderelated online searches.
Google Trends ® . It seems that the public's interest in tropicamide has increased over the last 5 years compared to the five previous years ( Figure 4 ). Since 2013, most of the searches come from Russia and Ukraine; before 2013, the number of searches was too small to warrant making any geographical distinctions.
Figure 1
Accumulated number of reports of suspicious requests to obtain tropicamide eye drops from community pharmacists between September 2014 and 5 July 2016
Figure 2
Evolution of geographical location of notifications of suspicious attempts to obtain tropicamide eye drops from community pharmacists as function of time (Midi-Pyrénées area, to 5 July 2016)
Figure 3
Reports of suspicious attempts to obtain tropicamide eye drops (France, to 5 July 2016)
Figure 4
Evolution of the interest in the search term 'tropicamide-chemical element' as a function of time (left) and geographical distribution (right) (extracted from Google Trends ® ) Media and Internet forums [16] [17] [18] [19] . According to the English newspaper The Independent in 2011, a young Russian man aged 25 died after repeated femoral artery injections of tropicamide eye drops. To our knowledge, this fatality was not reported in scientific publications. In online drug forums, subjects about tropicamide are rare but we cannot exclude the use of another 'street name' for the drug. Generally speaking, tropicamide seems to frighten: for some users it is one of the drugs contained in 'krokodil' (a substance renowned for necrosis-induced injection) or coming from 'the country that brought us krokodil abuse' and members appeared not to be attracted by this new risky trend. We found the testimony of a man who was present at a party where someone injected tropicamide in addition to taking cannabis and alcohol. He reported slow thought, confusional state, unresponsiveness and difficulty walking. Another user wrote his 'trip report' after tropicamide injection and described euphoria and dizziness with 0.5 ml, tachycardia and dry mouth with 1 ml. A member of drugsforum.com notes that mixing heroin and tropicamide is a known practice in Egypt.
Discussion
The misuse of tropicamide eye drops has been the subject of some sporadic case reports and studies. To our knowledge, the first publication of tropicamide abuse in 1975 reported the case of a 25-year-old man who developed tolerance and addiction to a topical use of tropicamide combined with cyclopentolate [20] . These eye drops were prescribed for ophthalmic indications, but the patient began to increase the dosage when not gaining relief. Abuse of cyclopentolate alone by topical and intranasal route was also reported in patients with psychiatric or substance abuse comorbidities [21] [22] [23] [24] . Aside from this, three case reports and a study were recently published, showing tropicamide non-medical use in opioid users among Eastern Europe and Central Asian citizens [25] [26] [27] (Table 3 ). All subjects reported injecting tropicamide, alone or in combination with heroin, to prolong or enhance pleasant heroin effects or decrease opioid consumption. Results of animal and human studies suggest that muscarinic antagonists would reduce the severity of opioid withdrawal symptoms and rewarding effects of morphine [28] [29] [30] . Tropicamide abusers declared consuming up to 1500 mg daily, whereas psychiatric adverse effects following a medical use appeared from 1 mg of tropicamide topical cumulative dose; this suggests a high drug tolerance. Systemic atropinic effects could lead to severe complications like urinary retention, paralytic ileus, acute angle-closure glaucoma or memory and behaviour disorders. To this can be added intravenous route-related complications such as skin infections, endocarditis, transmission of virus and overdose. This paper collects multi-sourced information on tropicamide diverted use proposing a comprehensive explanation of suspicious requests observed by French pharmacists. In 2014 and 2015, 17 falsified prescriptions (0.91%, 95% CI [0.53-1.46%])) collected on French territory involved tropicamide and more precisely the 10 ml bottle (compared with 0%, 95% CI [0-0.19%] for the six betablockers comparators over the same period). Moreover, 37 other suspicious prescriptions were presented in French pharmacies in 2015 (but only notified in 2016), resulting in an overall total of 54 prescriptions collected. The abuse potential of tropicamide eye drops could be supported by the fact that it was the only drug mentioned in 43 prescriptions among 54 presented between 2014 and 2015 and was associated with pregabalin in nine cases. Indeed, pregabalin is known to be diverted in patients on methadone maintenance or in multiple drug users, for sedative effects or recreational purposes (dissociative and euphoric effects notably sought), which may lead to dependence [31] [32] [33] [34] . Along with falsified prescriptions, spontaneous requests were reported by community pharmacists. On a regional scale, the network connecting the Midi-Pyrénées Health Authority, the Toulouse Addictovigilance Centre and community pharmacists permitted restriction to the access to tropicamide eye drops by warning a large number of professionals in the area from December 2014. In July 2015 a second alert was sent to all community pharmacists. From then, half of requests have led to a refusal to issue (65 requests, 33.8% of missing data). To date in France, details are lacking to determine the extent of the diverted use of tropicamide and if subjects obtain the eye drops for individual consumption or for drug trafficking purposes. Given the available (but not exhaustive) data of the 2016 OSIAP survey, the phenomenon continues to escalate (with at least 80 suspicious prescriptions of tropicamide recorded) and to be spreading (with six other areas concerned).
Conclusion
To our knowledge, these results represent the first early warning signs of tropicamide diverted use in France. As a single source of information is rarely sufficient to detect and evaluate an addictovigilance signal, we have combined different sources of information. Data collected support the hypothesis, suggesting an abuse in opioid users and, a priori, in a specific population coming from Eastern Europe and Central Asia. Through exchanges with local professionals working in structures specialized in addiction, welcoming drug users or migrants and refugees, this practice was not known. Tropicamide diverted use may be marginal in France, but as this practice is very high risk and may involve people who are not connected with care or support structures, health professionals and medico-social workers involved in drug users' care should be aware of the existence of this divergent use.
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